EUVIMEDEUVIMED entdecken
Crossref

Alzheimer’s drug approval gets a mixed reception

Jennifer Couzin-Frankel

Science · 2023

DOI: 10.1126/science.adg6275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, 2023. Verfasst von Jennifer Couzin-Frankel. Hauptthemen laut MEDLINE: Alzheimer Disease, Antibodies, Monoclonal, Humanized, Drug Approval. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

FDA allows use of antibody despite ongoing debates over its benefits and dangers

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAntibodies, Monoclonal, HumanizedDrug ApprovalHumansUnited StatesUnited States Food and Drug Administration

Substanzen

Antibodies, Monoclonal, Humanizedlecanemab

Zitieren

APA

Couzin-Frankel, J. (2023). Alzheimer’s drug approval gets a mixed reception. Science. https://doi.org/10.1126/science.adg6275

Vancouver

Couzin-Frankel J. Alzheimer’s drug approval gets a mixed reception. Science. 2023. doi:10.1126/science.adg6275

BibTeX
@article{CouzinFrankel2023,
  author = {Couzin-Frankel, Jennifer},
  title = {Alzheimer’s drug approval gets a mixed reception},
  journal = {Science},
  year = {2023},
  doi = {10.1126/science.adg6275}
}
Kostenlos starten →